Yichang Hec Changjiang Pharmaceutical Co. Ltd. held its Annual General Meeting on May 29, 2025. During the meeting, several proposals were reviewed and approved. These included the re-appointment of KPMG as auditor for a term until the next annual general meeting, the report of the Board of Directors for the year ended December 31, 2024, and the report of the Supervisory Committee for the same period. Additionally, the audited consolidated financial statements for the year ended December 31, 2024, were approved, as well as the profit distribution plan for the year. All proposals were passed as ordinary resolutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.